Schrodinger Inc (SDGR)

$13.38 -0.71 (-5.04%)
Market Cap 1.03B
Revenue (ttm) 207.54M
Net Income (ttm) -187.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.16%
Debt to Equity Ratio 0.00
Volume 1,592,100
Avg Vol 1,016,102
Day's Range N/A - N/A
Shares Out 73.67M
Stochastic %K 9%
Beta 1.54
Analysts Strong Sell
Price Target $25.00

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services
Sector: Healthcare
Phone: 212 295 5800
Address:
1540 Broadway, 24th Floor, New York, United States
Weber10
Weber10 Feb. 3 at 9:16 PM
$SDGR lots of chatter about Structure Therapeutics being bought out by some of the big boys... we own approximately 3% of the company so that would be a nice payout to us (between $150M-$200M) which would alleviate the cash crunch we are currently facing and lets us not sell our phase 1 assets for peanuts... we need a win badly as we sit below $1B valuation which is absolutely fucking ridiculous... increased my position so it probably has further to fall lol... no risk it no biscuit I guess.
0 · Reply
JasonCO
JasonCO Feb. 3 at 5:33 PM
$SDGR
0 · Reply
scott52
scott52 Feb. 3 at 5:23 PM
$SDGR So, it's ShitCo valuation time. I peg the nadir valuation @ cash + 1x revenue. That would put it at roughly a $700M valuation or about $9.50. Probably just need them to screw the pooch on guidance next time they talk. And that's not asking too much as revenue is soft and getting softer. US Biotech is in a depression and I don't honestly expect it to come out of it. I expect the US Biotech industry to just about completely disappear by 2040.
1 · Reply
Facade78
Facade78 Feb. 3 at 4:05 PM
$SDGR 97% inst own and still bleeding...
0 · Reply
Laddoom
Laddoom Feb. 3 at 3:31 AM
I wish I had the funds available now. I am hoping this negative market sentiment will persist for the next year, which will allow me to accumulate a significant capital amount. $SDGR
0 · Reply
Luk05
Luk05 Feb. 1 at 2:43 PM
$SDGR last minutes friday could be a reborn
1 · Reply
Src947
Src947 Jan. 31 at 2:29 AM
$SDGR think they may sell this one outright. $22-25?
0 · Reply
MikeyNJ
MikeyNJ Jan. 31 at 12:53 AM
$SDGR Been highly critical of management for the past few years and have been on the sidelines. Made some money selling put options when the stock traded down near the bottom of the range. But, today I dipped my feet back in the water and bought a little. Valuation has gotten really cheap and based on the recent PR, it looks like management is pivoting by looking to sell some proprietary assets. Risk/reward from current valuation looks compelling. I look for long term valuation plays which this now meets the criteria.
0 · Reply
beckman07
beckman07 Jan. 30 at 2:51 PM
$SDGR The ship sank.
0 · Reply
madnessofcrowds
madnessofcrowds Jan. 30 at 2:42 PM
$SDGR bought more. market is wrong about this one.
1 · Reply
Latest News on SDGR
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

Jan 12, 2026, 8:30 AM EST - 22 days ago

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

Jan 9, 2026, 7:04 AM EST - 25 days ago

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

LLY

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

Jan 9, 2026, 7:00 AM EST - 25 days ago

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 8:30 AM EST - 6 weeks ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Unlocking Hidden Value In Schrodinger's Box

Dec 2, 2025, 3:08 PM EST - 2 months ago

Unlocking Hidden Value In Schrodinger's Box

Schrödinger to Present at Jefferies London Healthcare Conference

Nov 6, 2025, 8:30 AM EST - 3 months ago

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 10:41 PM EST - 3 months ago

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Schrödinger Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 3 months ago

Schrödinger Reports Third Quarter 2025 Financial Results

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Oct 30, 2025, 7:30 AM EDT - 3 months ago

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Oct 22, 2025, 8:30 AM EDT - 3 months ago

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 3:05 PM EDT - 5 months ago

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Aug 27, 2025, 8:30 AM EDT - 5 months ago

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Schrödinger Announces Discontinuation of SGR-2921 Program

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Schrödinger Announces Discontinuation of SGR-2921 Program

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:20 PM EDT - 6 months ago

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Schrödinger Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Schrödinger Reports Second Quarter 2025 Financial Results

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 25, 2025, 8:30 AM EDT - 6 months ago

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 18, 2025, 10:25 AM EDT - 7 months ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Jul 17, 2025, 8:00 AM EDT - 7 months ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 27, 2025, 8:00 AM EDT - 7 months ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 13, 2025, 1:02 PM EDT - 8 months ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 12, 2025, 7:00 AM EDT - 8 months ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 6, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 5, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 4, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 8 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 5:00 PM EDT - 8 months ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 29, 2025, 8:00 AM EDT - 8 months ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 8 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 27, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 26, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 9 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 12:00 PM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

Schrödinger to Present at Jefferies Global Healthcare Conference

May 22, 2025, 8:30 AM EDT - 9 months ago

Schrödinger to Present at Jefferies Global Healthcare Conference

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 11:37 PM EDT - 9 months ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

Schrödinger Announces CFO Appointment

May 20, 2025, 6:30 AM EDT - 9 months ago

Schrödinger Announces CFO Appointment

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 14, 2025, 9:30 AM EDT - 9 months ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 5:59 PM EDT - 9 months ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 9 months ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:30 AM EDT - 9 months ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 23, 2025, 8:30 AM EDT - 10 months ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Weber10
Weber10 Feb. 3 at 9:16 PM
$SDGR lots of chatter about Structure Therapeutics being bought out by some of the big boys... we own approximately 3% of the company so that would be a nice payout to us (between $150M-$200M) which would alleviate the cash crunch we are currently facing and lets us not sell our phase 1 assets for peanuts... we need a win badly as we sit below $1B valuation which is absolutely fucking ridiculous... increased my position so it probably has further to fall lol... no risk it no biscuit I guess.
0 · Reply
JasonCO
JasonCO Feb. 3 at 5:33 PM
$SDGR
0 · Reply
scott52
scott52 Feb. 3 at 5:23 PM
$SDGR So, it's ShitCo valuation time. I peg the nadir valuation @ cash + 1x revenue. That would put it at roughly a $700M valuation or about $9.50. Probably just need them to screw the pooch on guidance next time they talk. And that's not asking too much as revenue is soft and getting softer. US Biotech is in a depression and I don't honestly expect it to come out of it. I expect the US Biotech industry to just about completely disappear by 2040.
1 · Reply
Facade78
Facade78 Feb. 3 at 4:05 PM
$SDGR 97% inst own and still bleeding...
0 · Reply
Laddoom
Laddoom Feb. 3 at 3:31 AM
I wish I had the funds available now. I am hoping this negative market sentiment will persist for the next year, which will allow me to accumulate a significant capital amount. $SDGR
0 · Reply
Luk05
Luk05 Feb. 1 at 2:43 PM
$SDGR last minutes friday could be a reborn
1 · Reply
Src947
Src947 Jan. 31 at 2:29 AM
$SDGR think they may sell this one outright. $22-25?
0 · Reply
MikeyNJ
MikeyNJ Jan. 31 at 12:53 AM
$SDGR Been highly critical of management for the past few years and have been on the sidelines. Made some money selling put options when the stock traded down near the bottom of the range. But, today I dipped my feet back in the water and bought a little. Valuation has gotten really cheap and based on the recent PR, it looks like management is pivoting by looking to sell some proprietary assets. Risk/reward from current valuation looks compelling. I look for long term valuation plays which this now meets the criteria.
0 · Reply
beckman07
beckman07 Jan. 30 at 2:51 PM
$SDGR The ship sank.
0 · Reply
madnessofcrowds
madnessofcrowds Jan. 30 at 2:42 PM
$SDGR bought more. market is wrong about this one.
1 · Reply
Mart7810
Mart7810 Jan. 30 at 1:39 AM
$SDGR did you ever said: I won't put a stop, it will go up soon?
0 · Reply
Mart7810
Mart7810 Jan. 30 at 1:37 AM
$SDGR
0 · Reply
Weber10
Weber10 Jan. 28 at 4:15 PM
$SDGR I agree with the old timers on this board... we need to sell those assets although Ramy probably doesn't want to make a deal from a position of weakness... guess we find out how secure his position is in the next few months... and questions about the validity of the platform are ridiculous. Lilly chose to use their software, that's a pretty fuckin big endorsement. Maybe we just drift lower or sideways until we get a deal done... I still believe in this company even though SP action past couple years has been a major drag on the portfolio.
0 · Reply
MikeyNJ
MikeyNJ Jan. 27 at 9:39 PM
$SDGR Was a bad business model from day 1. They are a good software company that wanted to also be a biotech. That takes way too much in resources and always threatens further dilution. I think they finally get it. I agree 100% with Scott52. Sell off all the molecules currently in trials and then do what they do best. Grow the software business and partner any proprietary programs that have any value going forward. This will keep the company cash flow positive and build a royalty platform down the line. If Ramy doesn't get it, then it's time to change leadership.
2 · Reply
Marty030
Marty030 Jan. 27 at 8:25 PM
$SDGR Eyes on the 25th of February. Recent deals suggest healthy focus on short term improvement of balance sheet / cash position and higher chance of short term profitability. Maybe sacrificing a % of the long term prospects, but these are birds in the sky anyway.
0 · Reply
scott52
scott52 Jan. 27 at 6:28 PM
$SDGR They are punishing Ramy. Sell these dev products. Get out of this business. Or we'll drive the stock down so far the board will have to fire you. I'm all for it. Ramy needs to go.
1 · Reply
JasonCO
JasonCO Jan. 27 at 6:16 PM
$SDGR
0 · Reply
wealth_king23
wealth_king23 Jan. 27 at 5:57 PM
$SDGR looks like shorts have her under full control. not unless they leave or any good news pop up, shes going nowhere but south
0 · Reply
Peacetoy0u
Peacetoy0u Jan. 27 at 5:32 PM
$SDGR WTF.. Endless dumping..
0 · Reply
Weber10
Weber10 Jan. 27 at 4:12 PM
$SDGR think that deal with Lilly and Mana AI will probably impact software growth going forward... does SDGR get a percentage or royalties from compounds discovered on those platforms? We need more details obviously but the SP action since those announcements reflects bad news... there used to be a SP floor due to those growing software revenues offsetting trial costs and easing dilution fears... if that has been removed, how low do we go?
1 · Reply
wealth_king23
wealth_king23 Jan. 27 at 1:29 PM
$SDGR what if it goes below 10? Thatd be so sweet
1 · Reply
Mart7810
Mart7810 Jan. 27 at 11:12 AM
$SDGR
0 · Reply